Since the introduction of chemotherapy for the treatment of childhood leukemia more than sixty years ago, the, prognosis for children with cancer has improved dramatically. The 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now approaching.80%. Despite these advances, several childhood cancers still have unacceptably low cure rates, and even when treatment is successful, the acute and long-term morbidity of current therapy can be substantial. The Children's Oncology Group (COG), the world's largest organization devoted exclusively to childhood and adolescent cancer research, was founded 12 years ago. The COG's multidisciplinary research team, comprised of more than 8,000 members, conducts research at more than 200 leading children's hospitals, universities, and cancer centers. This proposal is for COG, as part of NCI's new National Clinical Trials Network, to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches that range from targeted, small molecules to cellular therapies. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer to children with cancer and their families to participation in research that allows for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The COG research portfolio importantly also includes research trials focused on improving the quality of life children with cancer and survivors. The proposal is for support of the COG Group Operations Center, clinician-scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.

Public Health Relevance

The Children's Oncology Group (COG) is the world's largest organization devoted exclusively to childhood and adolescent cancer research. Over 200 leading children's hospitals, universities, and cancer centers across North America participate in COG research, which is focused on developing better treatments for all children with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA180886-01S3
Application #
8911907
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-11
Project End
2019-02-28
Budget Start
2014-04-11
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$229,232
Indirect Cost
$6,027
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Mascarenhas, Leo; Felgenhauer, Judy L; Bond, Mason C et al. (2016) Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer 63:493-8
Haugen, Maureen; Kelly, Katherine Patterson; Leonard, Marcia et al. (2016) Nurse-Led Programs to Facilitate Enrollment to Children's Oncology Group Cancer Control Trials. J Pediatr Oncol Nurs 33:387-91
Withycombe, Janice S; Andam-Mejia, Rachel; Dwyer, Annie et al. (2016) A Comprehensive Survey of Institutional Patient/Family Educational Practices for Newly Diagnosed Pediatric Oncology Patients: A Report From the Children's Oncology Group. J Pediatr Oncol Nurs :
Armenian, Saro H; Hudson, Melissa M; Chen, Ming Hui et al. (2016) Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk BMC Cardiovasc Disord 16:187
Isakoff, Michael S; Goldsby, Robert; Villaluna, Doojduen et al. (2016) Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer 63:370-1
Jakacki, Regina I; Cohen, Kenneth J; Buxton, Allen et al. (2016) Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol 18:1442-50
Farrar, Jason E; Schuback, Heather L; Ries, Rhonda E et al. (2016) Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Res 76:2197-205
Zhou, Rachel; Ng, Angela; Constine, Louis S et al. (2016) A Comparative Evaluation of Normal Tissue Doses for Patients Receiving Radiation Therapy for Hodgkin Lymphoma on the Childhood Cancer Survivor Study and Recent Children's Oncology Group Trials. Int J Radiat Oncol Biol Phys 95:707-11
Larsen, Eric C; Devidas, Meenakshi; Chen, Si et al. (2016) Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. J Clin Oncol 34:2380-8
Schwartz, Cindy L; Wexler, Leonard H; Krailo, Mark D et al. (2016) Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer 63:54-61

Showing the most recent 10 out of 210 publications